Literature DB >> 12168909

Prognostic significance of DNA topoisomerase IIalpha expression in human hepatocellular carcinoma. .

Akira Watanuki1, Susumu Ohwada, Toshio Fukusato, Fujio Makita, Tatsuya Yamada, Akihiro Kikuchi, Yasuo Morishita.   

Abstract

BACKGROUND: The biological significance of the nuclear enzyme DNA topoisomerase II in hepatocellular carcinoma (HCC) remains unclear.
MATERIALS AND METHODS: Using immunohistochemical staining methods, we examined the clinical significance of topo IIalpha (8D2) in surgically resected HCC, comparing the expression of both Ki-67 and p53, as well as various clinicopathological factors and prognosis.
RESULTS: The 70 HCC samples showed a positive, but heterogeneous pattern. The mean topo IIalpha labeling index (LI) was 14.1 +/- 15.1%, and ranged from 0.2 to 55.6, and the median topo IIalpha LI was 9.9%. The mean value of the topo IIalpha LI in p53-positive HCC cases (25.6 +/- 17.4) was significantly higher than that in p53-negative cases (10.3 +/- 12.3). HCC patients with lower topo IIalpha LI had significantly longer disease-free survival and exhibited a longer cumulative survival period than did those with higher topo lIalpha LI.
CONCLUSION: Topo IIalpha over-expression appears to be linked with a potentially aggressive tumor phenotype and may indicate tumor recurrence and cancer-related death in HCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168909

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

Review 1.  Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy.

Authors:  Yousaf Ali; Shafida Abd Hamid
Journal:  Tumour Biol       Date:  2015-10-20

2.  Global gene profiling of spontaneous hepatocellular carcinoma in B6C3F1 mice: similarities in the molecular landscape with human liver cancer.

Authors:  Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills
Journal:  Toxicol Pathol       Date:  2011-05-13       Impact factor: 1.902

3.  Prediction of long-term survival rates in patients undergoing curative resection for solitary hepatocellular carcinoma.

Authors:  Yi Cao; Zhelong Jiang; Shaohu Wang; Haoyang Zhang; Yi Jiang; Lizhi Lv
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

Review 4.  Advances in non-surgical management of primary liver cancer.

Authors:  Xiao Chen; Hai-Peng Liu; Mei Li; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

5.  Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.

Authors:  Wenge Dong; Yangyang Xie; Hai Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-06       Impact factor: 6.055

Review 6.  Molecular targeted therapy for hepatocellular carcinoma.

Authors:  Melanie Thomas
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

7.  Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma.

Authors:  Ji-Gang Qiu; Jia Fan; Yin-Kun Liu; Jian Zhou; Zhi Dai; Cheng Huang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-08       Impact factor: 4.553

8.  Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation.

Authors:  Hoi-Hung Chan; Tian-Huei Chu; Hsin-Fan Chien; Cheuk-Kwan Sun; E-Ming Wang; Huay-Ben Pan; Hsiao-Mei Kuo; Tsung-Hui Hu; Kwok-Hung Lai; Jiin-Tsuey Cheng; Ming-Hong Tai
Journal:  BMC Gastroenterol       Date:  2010-07-22       Impact factor: 3.067

Review 9.  Evolution of systemic therapy of advanced hepatocellular carcinoma.

Authors:  Thomas Yau; Pierre Chan; Richard Epstein; Ronnie-T Poon
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

10.  Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.

Authors:  C Hughes; A Murphy; C Martin; E Fox; M Ring; O Sheils; B Loftus; J O'Leary
Journal:  J Clin Pathol       Date:  2006-03-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.